Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01850602 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01850602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01850602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2013
Completion date
December 10, 2013
Enrollment
213 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis, hyperphosphatemia